| Resource | Count |
|---|
| drugs_alternate_names name | 2 |
| side_effects name | 2 |
| '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine | 1 |
| '5'-O-(N-(L-Prolyl)-Sulfamoyl)Adenosine | 1 |
| ((2r,3s,5r)-3-Hydroxy-5-(4-Hydroxy-2-Oxo-3,4-Dihydropyrimidin-1(2h)-Yl)-Tetrahydrofuran-2-Yl)Methyldihydrogen Phosphate | 1 |
| (1'r,2's)-9-(2-Hydroxy-3'-Keto-Cyclopenten-1-Yl)Adenine | 1 |
| (1,10 Phenanthroline)-(Tri-Carbon Monoxide) Rhenium (I) | 1 |
| (1-HYDROXY-1-PHOSPHONO-2-[1,1';3',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID | 1 |
| (1-HYDROXY-1-PHOSPHONO-2-[1,1';4',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID | 1 |
| (1-HYDROXYDODECANE-1,1-DIYL)BIS(PHOSPHONIC ACID) | 1 |
| (1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID) | 1 |
| (1-HYDROXYNONANE-1,1-DIYL)BIS(PHOSPHONIC ACID) | 1 |
| (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone | 1 |
| (1-Tert-Butyl-5-Hydroxy-1h-Pyrazol-4-Yl)-(6-Methanesulfonyl-4'-Methoxy-2-Methyl-Biphenyl-3-Yl)-Methanone | 1 |
| (10ALPHA,13ALPHA,14BETA,17ALPHA)-17-HYDROXYANDROST-4-EN-3-ONE | 1 |
| (10E,12Z)-octadeca-10,12-dienoic acid | 1 |
| (10R)-10-Formyl-5,8,10-Trideazafolic Acid | 1 |
| (10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one | 1 |
| (10S)-10-Formyl-5,8,10-Trideazafolic Acid | 1 |
| (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE | 1 |
| (11E)-OCTADEC-11-ENOIC ACID | 1 |
| (11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one | 1 |
| (11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE | 1 |
| (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione | 1 |
| (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE | 1 |
| (13S)-13-METHYLDODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17(2H,4H)-DIONE | 1 |
| (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL | 1 |
| (17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate | 1 |
| (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime | 1 |
| (1R)-1,2,2-TRIMETHYLPROPYL (R)-METHYLPHOSPHINATE | 1 |
| (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE | 1 |
| (1R)-1-(2-THIENYLACETYLAMINO)-1-(3-CARBOXYPHENYL)METHYLBORONIC ACID | 1 |
| (1R)-1-(2-THIENYLACETYLAMINO)-1-PHENYLMETHYLBORONIC ACID | 1 |
| (1R)-1-PHENYLETHYL 4-(ACETYLAMINO)BENZYLPHOSPHONATE | 1 |
| (1R)-1-{[(4'-METHOXY-1,1'-BIPHENYL-4-YL)SULFONYL]AMINO}-2-METHYLPROPYLPHOSPHONIC ACID | 1 |
| (1R)-2-METHYL-1-(PHENYLMETHYL)PROPYL[(1S)-1-FORMYLPENTYL]CARBAMATE | 1 |
| (1R)-2-PHENYLACETAMIDO-2-(3-CARBOXYPHENYL)ETHYL BORONIC ACID | 1 |
| (1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE | 1 |
| (1R)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol | 1 |
| (1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE | 1 |
| (1R)-3-chloro-1-phenylpropan-1-ol | 1 |
| (1R)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid | 1 |
| (1R)-MENTHYL HEXYL PHOSPHONATE GROUP | 1 |
| (1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE | 1 |
| (1R, 2S)-CIS 1,2 DIHYDROXY-1,2-DIHYDRONAPHTHALENE | 1 |
| (1R,2R)-N-(2-AMINOETHYL)-2-{[(4-METHOXYPHENYL)SULFONYL]METHYL}CYCLOHEXANECARBOXAMIDE | 1 |
| (1R,2R,3R,4S,5R)-4-(BENZYLAMINO)-5-(METHYLTHIO)CYCLOPENTANE-1,2,3-TRIOL | 1 |
| (1R,2S)-2-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)cyclohexanecarboxylic acid | 1 |
| (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol | 1 |
| (1R,3S,5S,8R)-8-HYDROXY-2-OXABICYCLO[3.3.1]NON-6-ENE-3,5-DICARBOXYLIC ACID | 1 |
| (1R,4S,7AS)-1-(1-FORMYLPROP-1-EN-1-YL)-4-METHOXY-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID | 1 |
| (1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOL | 1 |
| (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE | 1 |
| (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate | 1 |
| (1S)-1-(PHENOXYMETHYL)PROPYL METHYLPHOSPHONOCHLORIDOATE | 1 |
| (1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL | 1 |
| (1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE | 1 |
| (1S)-1-{[(4'-METHOXY-1,1'-BIPHENYL-4-YL)SULFONYL]AMINO}-2-METHYLPROPYLPHOSPHONIC ACID | 1 |
| (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE | 1 |
| (1S)-2-(1H-INDOL-3-YL)-1-{[(5-ISOQUINOLIN-6-YLPYRIDIN-3-YL)OXY]METHYL}ETHYLAMINE | 1 |
| (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE | 1 |
| (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE | 1 |
| (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate | 1 |
| (1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE | 1 |
| (1S)-MENTHYL HEXYL PHOSPHONATE GROUP | 1 |
| (1S,2R)-2-[(2,5-difluorophenyl)carbamoyl]cyclopropanecarboxylic acid | 1 |
| (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide | 1 |
| (1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL | 1 |
| (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE | 1 |
| (1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE | 1 |
| (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol | 1 |
| (1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL | 1 |
| (1S,3R,4S,5S,7S)-4-{[2-(4-METHOXYPHENOXY)-2-METHYLPROPANOYL]AMINO}ADAMANTANE-1-CARBOXAMIDE | 1 |
| (1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid | 1 |
| (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile | 1 |
| (1S,3aS,5aR,8aS)-1,7,7-trimethyl-1,2,3,3a,5a,6,7,8-octahydrocyclopenta[c]pentalene-4-carboxylic acid | 1 |
| (1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID | 1 |
| (1S,4R,9S)-5-(trifluoromethyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-9-amine | 1 |
| (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine | 1 |
| (1S,4S,5S)-1,4,5-TRIHYDROXY-3-[3-(PHENYLTHIO)PHENYL]CYCLOHEX-2-ENE-1-CARBOXYLIC ACID | 1 |
| (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE | 1 |
| (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE | 1 |
| (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE | 1 |
| (1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL | 1 |
| (1Z)-2-HYDROXY-3-OXOHEX-1-EN-1-YL DIHYDROGEN PHOSPHATE | 1 |
| (1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE | 1 |
| (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione | 1 |
| (1h-Indol-3-Yl)-(2-Mercapto-Ethoxyimino)-Acetic Acid | 1 |
| (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine | 1 |
| (1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol | 1 |
| (1r,4s)-2-Azabornane | 1 |
| (1s)-1(9-Deazahypoxanthin-9yl)1,4-Dideoxy-1,4-Imino-D-Ribitol-5-Phosphate | 1 |
| (1s)-1-(9-Deazaadenin-9-Yl)-1,4,5-Trideoxy-1,4-Imino-5-Methylthio-D-Ribitol | 1 |
| (1s,2s)-1-Amino-1-(1,3-Thiazol-2-Yl)Propan-2-Ol | 1 |
| (1s,3r,4r,6s)-1,3,4,6-Tetrapkisphosphate | 1 |
| (1s,3s,4s)-1,3,4-Triphospho-Myo-Inositol | 1 |
| (1s,6s,7r,8r,8ar)-1,6,7,8-Tetrahydroxyindolizidine | 1 |
| (2,2-DIPHOSPHONOETHYL)(DODECYL)DIMETHYLPHOSPHONIUM | 1 |
| (2,6-DIMETHYL-PHENOXY)-ACETIC ACID | 1 |
| (2-ACETYL-5-METHYLANILINO)(2,6-DIBROMOPHENYL)ACETAMIDE | 1 |
| (2-AMINO-1,3-OXAZOL-5-YL)-(3-BROMOPHENYL)METHANONE | 1 |
| (2-AMINO-3-PHENYL-BICYCLO[2.2.1]HEPT-2-YL)-PHENYL-METHANONE | 1 |
| (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE | 1 |
| (2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)ACETIC ACID | 1 |
| (2-Sulfanyl-3-Phenylpropanoyl)-Phe-Tyr | 1 |
| (2-[2-Ketopropylthio]Ethanesulfonate | 1 |
| (2-{[(4-BROMO-2-FLUOROBENZYL)AMINO]CARBONYL}-5-CHLOROPHENOXY)ACETIC ACID | 1 |
| (20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE | 1 |
| (20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE | 1 |
| (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE | 1 |
| (2E)-1-[(6-chloropyridin-3-yl)methyl]-N-nitroimidazolidin-2-imine | 1 |
| (2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one | 1 |
| (2E)-2-({(2S)-2-CARBOXY-2-[(PHENOXYACETYL)AMINO]ETHOXY}IMINO)PENTANEDIOIC ACID | 1 |
| (2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE | 1 |
| (2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID | 1 |
| (2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID | 1 |
| (2E)-3-(3,4-DIHYDROXYPHENYL)-N-[2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE | 1 |
| (2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid | 1 |
| (2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE | 1 |
| (2E)-3-{3-[(5-ETHYL-3-IODO-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-4-YL)OXY]PHENYL}ACRYLONITRILE | 1 |
| (2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide | 1 |
| (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide | 1 |
| (2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID | 1 |
| (2E,4E)-2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID | 1 |
| (2E,4R,5S)-2,3,4,5-TETRAHYDROXY-6-(PALMITOYLOXY)HEX-2-ENOIC ACID | 1 |
| (2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID | 1 |
| (2R)-1-(2,6-dimethylphenoxy)propan-2-amine | 1 |
| (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL | 1 |
| (2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine | 1 |
| (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL | 1 |
| (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL | 1 |
| (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL | 1 |
| (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL | 1 |
| (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE | 1 |
| (2R)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE | 1 |
| (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE | 1 |
| (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium | 1 |
| (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol | 1 |
| (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE | 1 |
| (2R)-2-ETHYL-1-HEXANESULFONIC ACID | 1 |
| (2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE | 1 |
| (2R)-2-benzyl-3-nitropropanoic acid | 1 |
| (2R)-2-{[(4-FLUORO-3-METHYLPHENYL)SULFONYL]AMINO}-N-HYDROXY-2-TETRAHYDRO-2H-PYRAN-4-YLACETAMIDE | 1 |
| (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol | 1 |
| (2R)-3-(phosphonooxy)propane-1,2-diyl diheptanoate | 1 |
| (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL | 1 |
| (2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID | 1 |
| (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE | 1 |
| (2R)-4,4-dihydroxy-5-nitro-2-(phenylmethyl)pentanoic acid | 1 |
| (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE | 1 |
| (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE | 1 |
| (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE | 1 |
| (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE | 1 |
| (2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide | 1 |
| (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide | 1 |
| (2R,3R)-3-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]AMINO}-2-CYANO-3-THIOXOPROPANAMIDE | 1 |
| (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine | 1 |
| (2R,3R)-N^1^-[(1S)-2,2-DIMETHYL-1-(METHYLCARBAMOYL)PROPYL]-N^4^-HYDROXY-2-(2-METHYLPROPYL)-3-{[(1,3-THIAZOL-2-YLCARBONYL)AMINO]METHYL}BUTANEDIAMIDE | 1 |
| (2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL | 1 |
| (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL | 1 |
| (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol | 1 |
| (2R,4R)-N~1~-(4-CHLOROPHENYL)-N~2~-[2-FLUORO-4-(2-OXOPYRIDIN-1(2H)-YL)PHENYL]-4-METHOXYPYRROLIDINE-1,2-DICARBOXAMIDE | 1 |
| (2R,4S)-2-[(R)-BENZYLCARBAMOYL-PHENYLACETYL-METHYL]-5,5-DIMETHYL-THIAZOLIDINE-4-CARBOXYLIC ACID | 1 |
| (2R,6S)-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-hexahydroquinazoline-2,4-diamine | 1 |
| (2S) N-ACETYL-L-ALANYL-ALPHAL-PHENYLALANYL-CHLOROETHYLKETONE | 1 |
| (2S)-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)(4-FLUOROPHENYL)ACETIC ACID | 1 |
| (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile | 1 |
| (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE | 1 |
| (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol | 1 |
| (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE | 1 |
| (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol | 1 |
| (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL | 1 |
| (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL | 1 |
| (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL | 1 |
| (2S)-1-methyl-2-[(2S,4R)-2-methyl-4-phenylpentyl]piperidine | 1 |
| (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL | 1 |
| (2S)-1-{[5-(1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-[(7AS)-7AH-INDOL-3-YL]PROPAN-2-AMINE | 1 |
| (2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE | 1 |
| (2S)-2-(1H-indol-3-yl)hexanoic acid | 1 |
| (2S)-2-(1H-indol-3-yl)pentanoic acid | 1 |
| (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one | 1 |
| (2S)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-[(S)-HYDROXY(3-PHENYLPROPYL)PHOSPHORYL]PROPANOIC ACID | 1 |
| (2S)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE | 1 |
| (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid | 1 |
| (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid | 1 |
| (2S)-2-(4-{[3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]OXY}PHENOXY)PROPANOIC ACID | 1 |
| (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid | 1 |
| (2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE | 1 |
| (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid | 1 |
| (2S)-2-({6-[(3-AMINO-5-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL | 1 |
| (2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE | 1 |
| (2S)-2-AMINO-4-(METHYLSULFANYL)-1-(1,3-THIAZOL-2-YL)BUTANE-1,1-DIOL | 1 |
| (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID | 1 |
| (2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID | 1 |
| (2S)-2-HYDROXYOCTANOIC ACID | 1 |
| (2S)-2-[(2,1,3-BENZOTHIADIAZOL-4-YLSULFONYL)AMINO]-2-PHENYL-N-PYRIDIN-4-YLACETAMIDE | 1 |
| (2S)-2-[(3aR,4R,7S,7aS)-1,3-dioxooctahydro-2H-4,7-methanoisoindol-2-yl]propanoic acid | 1 |
| (2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID | 1 |
| (2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID | 1 |
| (2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(R)-HYDROXY[(1R)-2-METHYL-1-{[(3-PHENYLPROPYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID | 1 |
| (2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID | 1 |
| (2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid | 1 |
| (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide | 1 |
| (2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine | 1 |
| (2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid | 1 |
| (2S)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol | 1 |
| (2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACID | 1 |
| (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID | 1 |
| (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide | 1 |
| (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid | 1 |
| (2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid | 1 |
| (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide | 1 |
| (2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE | 1 |
| (2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE | 1 |
| (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide | 1 |
| (2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide | 1 |
| (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide | 1 |
| (2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE | 1 |
| (2S)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydro-4H-chromen-4-one | 1 |
| (2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE | 1 |
| (2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid | 1 |
| (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide | 1 |
| (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE | 1 |
| (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE | 1 |
| (2S)-hydroxy(4-hydroxyphenyl)ethanoic acid | 1 |
| (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol | 1 |
| (2S,3S)-3-(4-fluorophenyl)-2,3-dihydroxypropanoic acid | 1 |
| (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE | 1 |
| (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE | 1 |
| (2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID | 1 |
| (2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID | 1 |
| (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine | 1 |
| (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE | 1 |
| (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine | 1 |
| (2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid | 1 |
| (2S,3S,4R,5R,6R)-5-Amino-2-(Aminomethyl)-6-((2R,3R,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-Diamino-2-((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-2-(hydroxymethyl)-4-(2-((R)-piperidin-3-ylmethylamin | 1 |
| (2S,4S,5R)-1-(4-TERT-BUTYLBENZOYL)-2-ISOBUTYL-5-(1,3-THIAZOL-2-YL)PYRROLIDINE-2,4-DICARBOXYLIC ACID | 1 |
| (2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID | 1 |
| (2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID | 1 |
| (2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide | 1 |
| (2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide | 1 |
| (2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE | 1 |
| (2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide | 1 |
| (2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide | 1 |
| (2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide | 1 |
| (2Z,3E)-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE 3-{O-[(3R)-3,4-DIHYDROXYBUTYL]OXIME} | 1 |
| (2Z,4E)-2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID | 1 |
| (2Z,4E)-3-chloro-2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid | 1 |
| (2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine | 1 |
| (2e,3s)-3-Hydroxy-5'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-One | 1 |
| (2r)-2,3-Dihydroxypropanal | 1 |
| (2r)-2-(Aminomethyl)-2,4-Dihydroxy-5-Oxo-3-(2-Oxoethyl)-2,5-Dihydro-1h-Imidazol-3-Ium | 1 |
| (2r)-2-{[Formyl(Hydroxy)Amino]Methyl}Hexanoic Acid | 1 |
| (2r)-Amino(3,5-Dihydroxyphenyl)Acetic Acid | 1 |
| (2r)-Amino(4-Hydroxyphenyl)Acetic Acid | 1 |
| (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide | 1 |
| (2r,3r,4r,5r)-3,4-Dihydroxy-N,N'-Bis[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-2,5-Bis(2-Phenylethyl)Hexanediamide | 1 |
| (2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium | 1 |
| (2r,4s)-2-Methyl-2,3,3,4-Tetrahydroxytetrahydrofuran | 1 |
| (2s)-2,8-Diaminooctanoic Acid | 1 |
| (2s)-2-Amino-4-(Methylsulfanyl)-1-Pyridin-2-Ylbutane-1,1-Diol | 1 |
| (2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid | 1 |
| (2s)-2-[(5-Benzofuran-2-Yl-Thiophen-2-Ylmethyl)-(2,4-Dichloro-Benzoyl)-Amino]-3-Phenyl-Propionic Acid | 1 |
| (2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid | 1 |
| (2s)-Amino(4-Hydroxyphenyl)Acetic Acid | 1 |
| (2s)-Hydroxy(4-Hydroxyphenyl)Ethanenitrile | 1 |
| (2s)-Pyrrolidin-2-Ylmethylamine | 1 |
| (2s,3r)-1-Amino-2-Methylbutane-2,3-Diol | 1 |
| (2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide | 1 |
| (2s,3s)-1,4-Dimercaptobutane-2,3-Diol | 1 |
| (2s,3s)-Trans-2,3-Dihydro-3-Hydroxyanthranilic Acid | 1 |
| (2s,3s)-Trans-Dihydroquercetin | 1 |
| (2s,3s,8s,9s)-3-Amino-9-Methoxy-2,6,8-Trimethyl-10-Phenyldeca-4,6-Dienoic Acid | 1 |
| (2s,4r)-1-Acetyl-N-[(1s)-4-[(Aminoiminomethyl)Amino]-1-(2-Benzothiazolylcarbonyl)Butyl]-4-Hydroxy-2-Pyrrolidinecarboxamide | 1 |
| (2s,4s)-Alpha-Campholinic Acid | 1 |
| (2s,5r,6r)-6-{[(6r)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-3,3-Dimethyl-7-Oxo-4-Thia-1-Azabicyclo[3.2.0]Heptane-2-Carboxylate | 1 |
| (2s,5s)-5-Carboxymethylproline | 1 |
| (2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid | 1 |
| (2z)-3-{[Oxido(Oxo)Phosphino]Oxy}-2-Phenylacrylate | 1 |
| (3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone | 1 |
| (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester | 1 |
| (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE | 1 |
| (3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium | 1 |
| (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium | 1 |
| (3-Chloro-4-Propoxy-Phenyl)-Acetic Acid | 1 |
| (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE | 1 |
| (3-EXO)-3-(10,11-DIHYDRO-5H-DIBENZO[A,D][7]ANNULEN-5-YLOXY)-8,8-DIMETHYL-8-AZONIABICYCLO[3.2.1]OCTANE | 1 |
| (3-Formyl-but-3-Enyl)-Phosphonic Acid | 1 |
| (3-{3-[[2-Chloro-3-(Trifluoromethyl)Benzyl](2,2-Diphenylethyl)Amino]Propoxy}Phenyl)Acetic Acid | 1 |
| (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE | 1 |
| (3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID | 1 |
| (3AR,5R,6S,7R,7AR)-5-(HYDROXYMETHYL)-2-PROPYL-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL | 1 |
| (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE | 1 |
| (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL | 1 |
| (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL | 1 |
| (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL | 1 |
| (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL | 1 |
| (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE | 1 |
| (3BETA)-CHOLEST-5-ENE-3,25-DIOL | 1 |
| (3BETA,20R)-CHOLEST-5-ENE-3,20-DIOL | 1 |
| (3BETA,7BETA)-CHOLEST-5-ENE-3,7-DIOL | 1 |
| (3E)-2,6-DIOXO-6-PHENYLHEX-3-ENOATE | 1 |
| (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one | 1 |
| (3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE | 1 |
| (3E)-4-(2-HYDROXYPHENYL)-2-OXOBUT-3-ENOIC ACID | 1 |
| (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime | 1 |
| (3R)-3-(FLUOROMETHYL)-7-(THIOMORPHOLIN-4-YLSULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE | 1 |
| (3R)-3-(FLUOROMETHYL)-N-(3,3,3-TRIFLUOROPROPYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | 1 |
| (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one | 1 |
| (3R)-3-HYDROXYDODECANOIC ACID | 1 |
| (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine | 1 |
| (3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide | 1 |
| (3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide | 1 |
| (3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid | 1 |
| (3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl 2,2-dimethylpropanoate | 1 |
| (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID | 1 |
| (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-(2,2,2-TRIFLUOROETHYL)-1,4-DIAZEPAN-2-ONE | 1 |
| (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE | 1 |
| (3R)-4-{[(3,4-dihydroxyphenyl)acetyl]oxy}-N-(2-formylindolizin-3-yl)-3-sulfino-D-valine | 1 |
| (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline | 1 |
| (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER | 1 |
| (3R)-N-(4-CHLOROPHENYL)-3-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | 1 |
| (3R)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | 1 |
| (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE | 1 |
| (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine | 1 |
| (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL | 1 |
| (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE | 1 |
| (3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL | 1 |
| (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol | 1 |
| (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol | 1 |
| (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE | 1 |
| (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE | 1 |
| (3R,4S,5S,7R,9E,11R,12R)-12-ETHYL-4-HYDROXY-3,5,7,11-TETRAMETHYLOXACYCLODODEC-9-ENE-2,8-DIONE | 1 |
| (3R,5S,7R,12S,13R)-13-FORMYL-12,14-DIHYDROXY-3,5,7-TRIMETHYLTETRADECANOIC ACID | 1 |
| (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE | 1 |
| (3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE | 1 |
| (3S)-1-(2-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid | 1 |
| (3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid | 1 |
| (3S)-1-CYCLOHEXYL-5-OXO-N-PHENYLPYRROLIDINE-3-CARBOXAMIDE | 1 |
| (3S)-1-CYCLOHEXYL-N-(3,5-DICHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXAMIDE | 1 |
| (3S)-1-{[4-(BUT-2-YN-1-YLOXY)PHENYL]SULFONYL}PYRROLIDINE-3-THIOL | 1 |
| (3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide | 1 |
| (3S)-3-hydroxy-1-methyl-2,3-dihydro-1H-indole-5,6-dione | 1 |
| (3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE | 1 |
| (3S)-N-(3-BROMOPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE | 1 |
| (3S)-N-(3-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE | 1 |
| (3S)-N-(5-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE | 1 |
| (3S)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | 1 |
| (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine | 1 |
| (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol | 1 |
| (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol | 1 |
| (3S,6S)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione | 1 |
| (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime | 1 |
| (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime | 1 |
| (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE | 1 |
| (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE | 1 |
| (3Z,5S,6R,7S,8R,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol | 1 |
| (3Z,5S,6R,7S,8R,8aS)-3-(octylimino)hexahydro[1,3]thiazolo[3,4-a]pyridine-5,6,7,8-tetrol | 1 |
| (3Z,5S,6R,7S,8S,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol | 1 |
| (3aS)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one | 1 |
| (3aS)-3a-hydroxy-5-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one | 1 |
| (3aS)-3a-hydroxy-7-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one | 1 |
| (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol | 1 |
| (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One | 1 |
| (3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime | 1 |
| (3r)-1-Acetyl-3-Methylpiperidine | 1 |
| (3r)-3-Methyl-L-Glutamic Acid | 1 |
| (3r)-3-{[(Benzyloxy)Carbonyl]Amino}-2-Oxo-4-Phenylbutane-1-Diazonium | 1 |
| (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine | 1 |
| (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester | 1 |
| (3r,4r,5r)-5-(Hydroxymethyl)Piperidine-3,4-Diol | 1 |
| (3r,5r)-7-((1r,2r,6s,8r,8as)-2,6-Dimethyl-8-{[(2r)-2-Methylbutanoyl]Oxy}-1,2,6,7,8,8a-Hexahydronaphthalen-1-Yl)-3,5-Dihydroxyheptanoic Acid | 1 |
| (3s)-2,3,4,5-Tetrahydropyridin-3-Amine | 1 |
| (3s)-3,4-Di-N-Hexanoyloxybutyl-1-Phosphocholine | 1 |
| (3s)-3-Amino-1-(Cyclopropylamino)Heptane-2,2-Diol | 1 |
| (3s)-Tetrahydrofuran-3-Yl (1r,2s)-3-[4-((1r)-2-{[(S)-Amino(Hydroxy)Methyl]Oxy}-2,3-Dihydro-1h-Inden-1-Yl)-2-Benzyl-3-Oxopyrrolidin-2-Yl]-1-Benzyl-2-Hydroxypropylcarbamate | 1 |
| (3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-{(1e,3e,7s,8s)-9-[(2s,3r,4s,5s,6r,9s,11s)-9-Ethyl-4-Hydroxy-3,5,11-Trimethyl-8-Oxo-1-Oxa-7-Azaspiro[5.5]Undec-2-Yl]-8-Hydroxy-1,7-Dimethylnona-1,3-Dienyl}-10,12-Dihydroxy-3-(3-Hydroxybenzyl)-6-Isopropyl-11-Methyl- | 1 |
| (3s,8ar)-3-(1h-Imidazol-5-Ylmethyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione | 1 |
| (3s,8ar)-3-(4-Hydroxybenzyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione | 1 |
| (4'-{[Allyl(Methyl)Amino]Methyl}-1,1'-Biphenyl-4-Yl)(4-Bromophenyl)Methanone | 1 |
| (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE | 1 |
| (4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE | 1 |
| (4-ETHYLPHENYL)SULFAMIC ACID | 1 |
| (4-Hydroxymaltosephenyl)Glycine | 1 |
| (4-fluorophenyl)(pyridin-4-yl)methanone | 1 |
| (4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester | 1 |
| (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid | 1 |
| (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid | 1 |
| (4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID | 1 |
| (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide | 1 |
| (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE | 1 |
| (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one | 1 |
| (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile | 1 |
| (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile | 1 |
| (4R)-N-[4-({[2-(DIMETHYLAMINO)ETHYL]AMINO}CARBONYL)-1,3-THIAZOL-2-YL]-4-METHYL-1-OXO-2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLINE-6-CARBOXAMIDE | 1 |
| (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE | 1 |
| (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE | 1 |
| (4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID | 1 |
| (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid | 1 |
| (4Z)-2,8:7,12:11,15:14,18:17,22-PENTAANHYDRO-4,5,6,9,10,13,19,20,21-NONADEOXY-D-ARABINO-D-ALLO-D-ALLO-DOCOSA-4,9,20-TRIENITOL | 1 |
| (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione | 1 |
| (4aS)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2H-dibenzo[b,f]azepin-8-ol | 1 |
| (4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate | 1 |
| (4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium | 1 |
| (4e)-4-Aminohex-4-Enoic Acid | 1 |
| (4e,8e,12z,16z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-Pentaen-1-Amine | 1 |
| (4r)-2-Methylpentane-2,4-Diol | 1 |
| (4r)-7aza-7,8-Dihydrolimonene | 1 |
| (4r,5s,6s,7r)-1,3-Dibenzyl-4,7-Bis(Phenoxymethyl)-5,6-Dihydroxy-1,3 Diazepan-2-One | 1 |
| (4s)-2-[(1e)-1-Aminoprop-1-Enyl]-4,5-Dihydro-1,3-Thiazole-4-Carboxylic Acid | 1 |
| (4s)-4-{[(2s)-2-Amino-3-Oxopropyl]Sulfanyl}-L-Homoserinate | 1 |
| (4s)-5-Fluoro-L-Leucine | 1 |
| (4s,5s)-1,2-Dithiane-4,5-Diol | 1 |
| (4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide | 1 |
| (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC | 1 |
| (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 1 |
| (5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone | 1 |
| (5-BROMO-4-CHLORO-3-INDOLYL)-A-D-MANNOSE | 1 |
| (5-CHLORO-2-{[(3-NITROBENZYL)AMINO]CARBONYL}PHENOXY)ACETIC ACID | 1 |
| (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine | 1 |
| (5-Methyl-6-Oxo-1,6-Dihydro-Pyridin-3-Yl)-1,2-Dideoxy-Ribofuranose-5-Monophosphate | 1 |
| (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid | 1 |
| (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol | 1 |
| (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL | 1 |
| (5BETA)-PREGNANE-3,20-DIONE | 1 |
| (5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE | 1 |
| (5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE | 1 |
| (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE | 1 |
| (5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID | 1 |
| (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid | 1 |
| (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime | 1 |
| (5R)-2-SULFANYL-5-[4-(TRIFLUOROMETHYL)BENZYL]-1,3-THIAZOL-4-ONE | 1 |
| (5R)-2-[(2-fluorophenyl)amino]-5-(1-methylethyl)-1,3-thiazol-4(5H)-one | 1 |
| (5R)-4-HYDROXY-3,5-DIMETHYL-5-[(1E,3E)-2-METHYLPENTA-1,3-DIENYL]THIOPHEN-2(5H)-ONE | 1 |
| (5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE | 1 |
| (5R)-5-[(1E)-BUTA-1,3-DIENYL]-4-HYDROXY-3,5-DIMETHYLTHIOPHEN-2(5H)-ONE | 1 |
| (5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE | 1 |
| (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid | 1 |
| (5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE | 1 |
| (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol | 1 |
| (5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one | 1 |
| (5S)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one | 1 |
| (5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one | 1 |
| (5S)-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}-5-(1-hydroxy-1-methylethyl)-5-methyl-1,3-thiazol-4(5H)-one | 1 |
| (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE | 1 |
| (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide | 1 |
| (5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide | 1 |
| (5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE | 1 |
| (5S,6S)-6-[(R)ACETOXYETH-2-YL]-PENEM-3-CARBOXYLATEPROPANE | 1 |
| (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE | 1 |
| (5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE | 1 |
| (5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE | 1 |
| (5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE | 1 |
| (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE | 1 |
| (5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-2-{[(S)-(4-FLUOROPHENYL)(1H-TETRAZOL-5-YL)METHYL]AMINO}-1,3-THIAZOL-4(5H)-ONE | 1 |
| (5e,13e)-9,15-Dihydroxy-11-Oxoprosta-5,13-Dien-1-Oicacid | 1 |
| (5r)-5-Amino-6-Hydroxyhexylcarbamic Acid | 1 |
| (5r)-6-(4-{[2-(3-Iodobenzyl)-3-Oxocyclohex-1-En-1-Yl]Amino}Phenyl)-5-Methyl-4,5-Dihydropyridazin-3(2h)-One | 1 |
| (5r,6s,7s,8s)-5-Hydroxymethyl-6,7,8-Trihydroxy-Tetrazolo[1,5-a]Piperidine | 1 |
| (5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione | 1 |
| (5z)-2-[(1s,2r)-1-Amino-2-Hydroxypropyl]-5-[(4-Amino-1h-Indol-3-Yl)Methylene]-3-(2-Hydroxyethyl)-3,5-Dihydro-4h-Imidazol-4-One | 1 |
| (5z)-5-(1h-Indol-3-Ylmethylene)-4h-Imidazol-4-One | 1 |
| (6,7-Difluoro-Quinazolin-4-Yl)-(1-Methyl-2,2-Diphenyl-Ethyl)-Amine | 1 |
| (6,7-Dihydro-5h-Cyclopenta[D]Imidazo[2,1-B]Thiazol-2-Yl]-4,7-Dihydro[1,4]Thiazepine-3,6-Dicarboxylic Acid | 1 |
| (6-METHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL)METHYLPHOSPHINATE | 1 |
| (6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL | 1 |
| (6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE | 1 |
| (6E)-7-{6-[(1E)-OCT-1-ENYL]-2,3-DIAZABICYCLO[2.2.1]HEPT-2-EN-5-YL}HEPT-6-ENOIC ACID | 1 |
| (6E,11E)-HEPTADECA-6,11-DIENE-9,9-DIYLBIS(PHOSPHONIC ACID) | 1 |
| (6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one | 1 |
| (6S)-1-chloro-3-[(4-fluorobenzyl)oxy]-6-(pyrrolidin-1-ylcarbonyl)pyrrolo[1,2-a]pyrazin-4(6H)-one | 1 |
| (6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one | 1 |
| (6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE | 1 |
| (6e)-6-[(2e,4e,6e)-3,7-Dimethylnona-2,4,6,8-Tetraenylidene]-1,5,5-Trimethylcyclohexene | 1 |
| (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin | 1 |
| (6r,7r)-3-[(Acetyloxy)Methyl]-7-{[(6s)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Octane-2-Carboxylate | 1 |
| (6s)-5,6,7,8-Tetrahydrofolate | 1 |
| (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine | 1 |
| (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one | 1 |
| (7as,12ar,12bs)-1,2,3,4,7a,12,12a,12b-Octahydroindolo[2,3-a]Quinolizin-7(6h)-One | 1 |
| (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid | 1 |
| (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid | 1 |
| (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid | 1 |
| (8ar)-Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione | 1 |
| (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL | 1 |
| (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL | 1 |
| (9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE | 1 |
| (9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM | 1 |
| (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid | 1 |
| (9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acid | 1 |
| (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid | 1 |
| (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one | 1 |
| (9r,10r)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene | 1 |
| (9s,10s)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene | 1 |
| (Aminooxy)Acetic Acid | 1 |
| (C8-R)-Hydantocidin 5'-Phosphate | 1 |
| (C8-S)-Hydantocidin 5'-Phosphate | 1 |
| (CHLOROACETYL)CARBAMIC ACID (3R,4S,5S,5R)-5-METHOXY-4-[(2R,3R)-2-METHYL-3-(3-METHYL-2-BUTENYL)OXIRANYL]-1-OXASPIRO[2.5]OCT-6-YL ESTER | 1 |
| (Carboxyhydroxyamino)Ethanoic Acid | 1 |
| (Diaminomethyl-Methyl-Amino)-Acetic Acid | 1 |
| Skipped 13,879 rows |
|---|
| terbinafine_increases_auc_venlafaxine | 1 |
| terbinafine_inhibits_cyp2d6 | 1 |
| terbutaline | 1 |
| teriflunomide | 1 |
| teriflunomide is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9 | 1 |
| teriflunomide is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9 | 1 |
| teriflunomide_does_not_inhibit_cyp2c9 | 1 |
| teriflunomide_inhibits_cyp2c9 | 1 |
| tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate | 1 |
| tert-butyl [(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]carbamate | 1 |
| testicle pain | 1 |
| testicular swelling | 1 |
| testosterone | 1 |
| testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4 | 1 |
| tetany | 1 |
| tetracycline | 1 |
| tetrahydrozoline | 1 |
| tetralogy of Fallot | 1 |
| thalassemia | 1 |
| theophylline | 1 |
| theophylline_has_metabolite_1,3-dimethyluric-acid | 1 |
| theophylline_has_metabolite_1-methylxanthine | 1 |
| theophylline_has_metabolite_3-methylxanthine | 1 |
| theophylline_has_metabolite_caffeine | 1 |
| theophylline_in_vitro_probe_substrate_of_enzyme_cyp1a2 | 1 |
| theophylline_primary_total_clearance_enzyme_cyp1a2 | 1 |
| theophylline_primary_total_clearance_mechanism_Metabolic_Clearance | 1 |
| therapeutic abortion | 1 |
| thiabendazole | 1 |
| thinking abnormal | 1 |
| thioridazine | 1 |
| thioridazine | 1 |
| thioridazine-5-sulfoxide | 1 |
| thioridazine_does_not_inhibit_cyp2c19 | 1 |
| thioridazine_has_metabolite_mesoridazine | 1 |
| thioridazine_has_metabolite_sulforidazine | 1 |
| thioridazine_has_metabolite_thioridazine-5-sulfoxide | 1 |
| thioridazine_inhibition_constant_cyp2d6 | 1 |
| thioridazine_inhibits_cyp2c19 | 1 |
| thioridazine_is_not_substrate_of_cyp2d6 | 1 |
| thioridazine_primary_total_clearance_enzyme_cyp2d6 | 1 |
| thioridazine_substrate_of_cyp2d6 | 1 |
| thiotepa | 1 |
| thiothixene | 1 |
| thiothixene_does_not_inhibit_cyp2c19 | 1 |
| thiothixene_inhibition_constant_cyp2d6 | 1 |
| thiothixene_inhibits_cyp2c19 | 1 |
| thoracotomy | 1 |
| threadworm | 1 |
| threohydrobupropion | 1 |
| threohydrobupropion_maximum_concentration_continuous_value | 1 |
| threohydrobupropion_primary_total_clearance_mechanism_Renal_Excretion | 1 |
| thromboangiitis obliterans | 1 |
| thrombophilia | 1 |
| thrombophlebitis | 1 |
| thrombophlebitis superficial | 1 |
| thrombotic thrombocytopenic purpura | 1 |
| thyroid adenoma | 1 |
| thyroid disorder | 1 |
| thyroid neoplasia | 1 |
| thyroid nodules | 1 |
| thyroidectomy | 1 |
| thyroiditis | 1 |
| thyrotoxicosis | 1 |
| ticlopidine | 1 |
| ticlopidine increases the AUC of bupropion | 1 |
| ticlopidine_increases_auc_bupropion | 1 |
| ticlopidine_inhibition_constant_cyp2b6 | 1 |
| ticlopidine_inhibition_constant_cyp2c19 | 1 |
| tiludronic acid | 1 |
| tinnitus | 1 |
| tolazamide | 1 |
| tolazoline | 1 |
| tolbutamide | 1 |
| tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9 | 1 |
| tolbutamide_primary_total_clearance_enzyme_cyp2c9 | 1 |
| tolmetin | 1 |
| tongue carcinoma | 1 |
| tonsillectomy | 1 |
| tooth caries | 1 |
| tooth disorder | 1 |
| topiramate | 1 |
| topiramate_does_not_inhibit_cyp1a2 | 1 |
| topiramate_does_not_inhibit_cyp2a6 | 1 |
| topiramate_does_not_inhibit_cyp2b6 | 1 |
| topiramate_does_not_inhibit_cyp2c19 | 1 |
| topiramate_does_not_inhibit_cyp2c9 | 1 |
| topiramate_does_not_inhibit_cyp2d6 | 1 |
| topiramate_does_not_inhibit_cyp2e1 | 1 |
| topiramate_does_not_inhibit_cyp3a4 | 1 |
| topiramate_does_not_inhibit_cyp3a5 | 1 |
| topiramate_inhibits_cyp1a2 | 1 |
| topiramate_inhibits_cyp2a6 | 1 |
| topiramate_inhibits_cyp2b6 | 1 |
| topiramate_inhibits_cyp2c19 | 1 |
| topiramate_inhibits_cyp2c9 | 1 |
| topiramate_inhibits_cyp2d6 | 1 |
| topiramate_inhibits_cyp2e1 | 1 |
| topiramate_inhibits_cyp3a4 | 1 |
| topiramate_inhibits_cyp3a5 | 1 |
| topiramate_primary_total_clearance_mechanism_Renal_Excretion | 1 |
| toremifene | 1 |
| torsemide | 1 |
| torticollis | 1 |
| toxic epidermal necrolysis | 1 |
| toxic goiter | 1 |
| toxic shock syndrome | 1 |
| tracheitis | 1 |
| tracheobronchitis | 1 |
| tracheostomy | 1 |
| trans NV-04 | 1 |
| trans-2-hydroxycinnamic acid | 1 |
| trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium | 1 |
| trans-urocanic acid | 1 |
| transdermal testosterone gel | 1 |
| transient amnesia | 1 |
| transient cerebral ischemia | 1 |
| transient global amnesia | 1 |
| transient hallucinations | 1 |
| transient ischemic attack | 1 |
| transposition of the great vessels | 1 |
| transurethral resection of the prostate | 1 |
| transverse myelitis | 1 |
| trauma | 1 |
| trazodone | 1 |
| trazodone_bioavailability_continuous_value | 1 |
| trazodone_has_metabolite_M-chlorophenylpiperazine | 1 |
| trazodone_is_not_substrate_of_cyp3a4 | 1 |
| trazodone_maximum_concentration_continuous_value | 1 |
| trazodone_primary_total_clearance_mechanism_Renal_Excretion | 1 |
| trazodone_substrate_of_cyp3a4 | 1 |
| triacetyl uridine | 1 |
| triazolam | 1 |
| triazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4 | 1 |
| triazolam_increases_auc_nefazodone | 1 |
| triazolam_primary_total_clearance_enzyme_cyp3a4 | 1 |
| tributylstannanyl | 1 |
| trichomonal vaginitis | 1 |
| trifascicular block | 1 |
| trifluoperazine | 1 |
| trigger finger | 1 |
| trimethoprim | 1 |
| trimethoprim is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C8 | 1 |
| trimethoprim_does_not_inhibit_cyp2c8 | 1 |
| trimethoprim_inhibits_cyp2c8 | 1 |
| tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate | 1 |
| troleandomycin | 1 |
| troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4 | 1 |
| tropical sprue | 1 |
| tropicamide | 1 |
| trovafloxacin | 1 |
| tubal ligation | 1 |
| tubal pregnancy | 1 |
| ulcerative proctitis | 1 |
| ulcerative stomatitis | 1 |
| umbilical hernia | 1 |
| unconsciousness | 1 |
| undecan-2-one | 1 |
| unsteady gait | 1 |
| upper GI bleeding | 1 |
| upper respiratory tract infection | 1 |
| urate crystalluria | 1 |
| uremia | 1 |
| ureteral obstruction | 1 |
| urinary frequency | 1 |
| urinary hesitancy | 1 |
| urinary incontinence | 1 |
| urinary obstruction | 1 |
| urinary outflow obstruction | 1 |
| urinary urgency | 1 |
| urogenital anomaly | 1 |
| urolithiasis | 1 |
| urosepsis | 1 |
| uterine hemorrhage | 1 |
| uterine sarcoma | 1 |
| vaginal discharge | 1 |
| vaginal dysplasia | 1 |
| vaginal hemorrhage | 1 |
| vaginal hysterectomy | 1 |
| vaginal moniliasis | 1 |
| vaginal pruritus | 1 |
| vaginitis | 1 |
| valproate | 1 |
| valproate increases the AUC of hydroxybupropion | 1 |
| valproate_increases_auc_aripiprazole | 1 |
| valproate_increases_auc_bupropion | 1 |
| valproate_increases_auc_hydroxybupropion | 1 |
| valproate_primary_total_clearance_mechanism_Metabolic_Clearance | 1 |
| valvular heart disease | 1 |
| vapitadine dihydrochloride | 1 |
| varicocele | 1 |
| varicose vein | 1 |
| vascular anomaly | 1 |
| vascular headache | 1 |
| vasovagal reaction | 1 |
| vegetarian | 1 |
| venereal disease | 1 |
| venlafaxine | 1 |
| venlafaxine increases the AUC of desipramine | 1 |
| venlafaxine increases the AUC of haloperidol | 1 |
| venlafaxine increases the AUC of imipramine | 1 |
| venlafaxine increases the AUC of risperidone | 1 |
| venlafaxine is predicted to reduce the clearance of aripiprazole by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of clozapine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of desipramine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of duloxetine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of escitalopram by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of fluoxetine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of fluvoxamine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of iloperidone by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of mirtazapine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of olanzapine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of paroxetine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of perphenazine by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of r-citalopram by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of risperidone by inhibition of CYP2D6 | 1 |
| venlafaxine is predicted to reduce the clearance of thioridazine by inhibition of CYP2D6 | 1 |
| venlafaxine_does_not_inhibit_cyp1a2 | 1 |
| venlafaxine_does_not_inhibit_cyp2c9 | 1 |
| venlafaxine_does_not_inhibit_cyp2d6 | 1 |
| venlafaxine_does_not_inhibit_cyp3a4 | 1 |
| venlafaxine_fraction_absorbed_continuous_value | 1 |
| venlafaxine_has_metabolite_N-desmethylvenlafaxine | 1 |
| venlafaxine_has_metabolite_O-desmethylvenlafaxine | 1 |
| venlafaxine_increases_auc_9-hydroxyrisperidone | 1 |
| venlafaxine_increases_auc_alprazolam | 1 |
| venlafaxine_increases_auc_desipramine | 1 |
| venlafaxine_increases_auc_haloperidol | 1 |
| venlafaxine_increases_auc_imipramine | 1 |
| venlafaxine_increases_auc_risperidone | 1 |
| venlafaxine_inhibits_cyp1a2 | 1 |
| venlafaxine_inhibits_cyp2c9 | 1 |
| venlafaxine_inhibits_cyp2d6 | 1 |
| venlafaxine_inhibits_cyp3a4 | 1 |
| venlafaxine_is_not_substrate_of_cyp2d6 | 1 |
| venlafaxine_is_not_substrate_of_cyp3a4 | 1 |
| venlafaxine_maximum_concentration_continuous_value | 1 |
| venlafaxine_primary_total_clearance_enzyme_cyp2d6 | 1 |
| venlafaxine_primary_total_clearance_mechanism_Metabolic_Clearance | 1 |
| venlafaxine_substrate_of_cyp2d6 | 1 |
| venlafaxine_substrate_of_cyp3a4 | 1 |
| venous insufficiency | 1 |
| venous thrombosis | 1 |
| ventricular extrasystoles | 1 |
| ventricular fibrillation | 1 |
| ventricular tachycardia | 1 |
| verapamil | 1 |
| verapamil increases the AUC of imipramine | 1 |
| verapamil increases the AUC of risperidone | 1 |
| verapamil is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of alprazolam by inhibition of CYP3A5 | 1 |
| verapamil is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of clozapine by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of duloxetine by inhibition of CYP1A2 | 1 |
| verapamil is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of mirtazapine by inhibition of CYP1A2 | 1 |
| verapamil is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A5 | 1 |
| verapamil is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of perphenazine by inhibition of CYP1A2 | 1 |
| verapamil is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of risperidone by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of trazodone by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of triazolam by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4 | 1 |
| verapamil is predicted to reduce the clearance of zolpidem by inhibition of CYP3A5 | 1 |
| verapamil_does_not_inhibit_cyp1a2 | 1 |
| verapamil_does_not_inhibit_cyp3a4 | 1 |
| verapamil_does_not_inhibit_cyp3a5 | 1 |
| verapamil_increases_auc_imipramine | 1 |
| verapamil_increases_auc_risperidone | 1 |
| verapamil_inhibits_cyp1a2 | 1 |
| verapamil_inhibits_cyp3a4 | 1 |
| verapamil_inhibits_cyp3a5 | 1 |
| verruca | 1 |
| vertebral fracture | 1 |
| viral hepatitis | 1 |
| viral infection | 1 |
| viral syndrome | 1 |
| visual field defect | 1 |
| visual hallucinations | 1 |
| visual halos | 1 |
| vitamin B deficiency | 1 |
| vitamin B12 deficiency | 1 |
| vitamin deficiency | 1 |
| vitreous detachment | 1 |
| vitreous floaters | 1 |
| vitreous hemorrhage | 1 |
| vocal cord paralysis | 1 |
| voice alteration | 1 |
| volvulus | 1 |
| von Willebrand disease | 1 |
| voriconazole | 1 |
| voriconazole is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of citalopram by inhibition of CYP2C19 | 1 |
| voriconazole is predicted to reduce the clearance of clozapine by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9 | 1 |
| voriconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of risperidone by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9 | 1 |
| voriconazole is predicted to reduce the clearance of sertraline by inhibition of CYP2C19 | 1 |
| voriconazole is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of trazodone by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of triazolam by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4 | 1 |
| voriconazole is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4 | 1 |
| voriconazole-N-oxide | 1 |
| voriconazole-N-oxide_does_not_inhibit_cyp2c19 | 1 |
| voriconazole-N-oxide_does_not_inhibit_cyp2c9 | 1 |
| voriconazole-N-oxide_does_not_inhibit_cyp3a4 | 1 |
| voriconazole-N-oxide_inhibits_cyp2c19 | 1 |
| voriconazole-N-oxide_inhibits_cyp2c9 | 1 |
| voriconazole-N-oxide_inhibits_cyp3a4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of citalopram by inhibition of CYP2C19 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of clozapine by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of risperidone by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of sertraline by inhibition of CYP2C19 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of trazodone by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of triazolam by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4 | 1 |
| voriconazole-n-oxide is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4 | 1 |
| voriconazole_bioavailability_continuous_value | 1 |
| voriconazole_does_not_inhibit_cyp2c19 | 1 |
| voriconazole_does_not_inhibit_cyp2c9 | 1 |
| voriconazole_does_not_inhibit_cyp3a4 | 1 |
| voriconazole_has_metabolite_voriconazole-N-oxide | 1 |
| voriconazole_inhibits_cyp2c19 | 1 |
| voriconazole_inhibits_cyp2c9 | 1 |
| voriconazole_inhibits_cyp3a4 | 1 |
| voriconazole_is_not_substrate_of_cyp2c19 | 1 |
| voriconazole_is_not_substrate_of_cyp2c9 | 1 |
| voriconazole_is_not_substrate_of_cyp3a4 | 1 |
| voriconazole_maximum_concentration_continuous_value | 1 |
| voriconazole_primary_total_clearance_enzyme_cyp2c19 | 1 |
| voriconazole_primary_total_clearance_mechanism_Metabolic_Clearance | 1 |
| voriconazole_substrate_of_cyp2c19 | 1 |
| voriconazole_substrate_of_cyp2c9 | 1 |
| voriconazole_substrate_of_cyp3a4 | 1 |
| vulval abscess | 1 |
| vulvitis | 1 |
| vulvovaginitis | 1 |
| warfarin | 1 |
| warfarin_primary_total_clearance_enzyme_cyp2c9 | 1 |
| watery eyes | 1 |
| weakness | 1 |
| weight gain | 1 |
| wheezing | 1 |
| white blood cell count increased | 1 |
| worry | 1 |
| wound dehiscence | 1 |
| wrist pain | 1 |
| xanthomas | 1 |
| xerosis | 1 |
| zafirlukast | 1 |
| zafirlukast is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of clozapine by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9 | 1 |
| zafirlukast is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of risperidone by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9 | 1 |
| zafirlukast is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of trazodone by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of triazolam by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4 | 1 |
| zafirlukast is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4 | 1 |
| zafirlukast_does_not_inhibit_cyp2c9 | 1 |
| zafirlukast_does_not_inhibit_cyp3a4 | 1 |
| zafirlukast_inhibits_cyp2c9 | 1 |
| zafirlukast_inhibits_cyp3a4 | 1 |
| zafirlukast_is_not_substrate_of_cyp2c9 | 1 |
| zafirlukast_maximum_concentration_continuous_value | 1 |
| zafirlukast_substrate_of_cyp2c9 | 1 |
| zaleplon | 1 |
| zaleplon_bioavailability_continuous_value | 1 |
| zaleplon_is_not_substrate_of_cyp2d6 | 1 |
| zaleplon_is_not_substrate_of_cyp3a4 | 1 |
| zaleplon_primary_total_clearance_mechanism_Metabolic_Clearance | 1 |
| zaleplon_substrate_of_cyp2d6 | 1 |
| zaleplon_substrate_of_cyp3a4 | 1 |
| zileuton | 1 |
| ziprasidone | 1 |
| ziprasidone-sulphoxide | 1 |
| ziprasidone_does_not_inhibit_cyp1a2 | 1 |
| ziprasidone_does_not_inhibit_cyp2c19 | 1 |
| ziprasidone_does_not_inhibit_cyp2c9 | 1 |
| ziprasidone_does_not_inhibit_cyp2d6 | 1 |
| ziprasidone_does_not_inhibit_cyp3a4 | 1 |
| ziprasidone_has_metabolite_S-methyl-dihydroziprasidone | 1 |
| ziprasidone_has_metabolite_benzisothiazole-sulphone | 1 |
| ziprasidone_has_metabolite_benzisothiazole-sulphoxide | 1 |
| ziprasidone_has_metabolite_ziprasidone-sulphoxide | 1 |
| ziprasidone_inhibition_constant_cyp2d6 | 1 |
| ziprasidone_inhibits_cyp1a2 | 1 |
| ziprasidone_inhibits_cyp2c19 | 1 |
| ziprasidone_inhibits_cyp2c9 | 1 |
| ziprasidone_inhibits_cyp2d6 | 1 |
| ziprasidone_inhibits_cyp3a4 | 1 |
| ziprasidone_is_not_substrate_of_cyp1a2 | 1 |
| ziprasidone_is_not_substrate_of_cyp2c19 | 1 |
| ziprasidone_is_not_substrate_of_cyp2c9 | 1 |
| ziprasidone_is_not_substrate_of_cyp2d6 | 1 |
| ziprasidone_is_not_substrate_of_cyp3a4 | 1 |
| ziprasidone_maximum_concentration_continuous_value | 1 |
| ziprasidone_primary_total_clearance_mechanism_Metabolic_Clearance | 1 |
| ziprasidone_substrate_of_cyp1a2 | 1 |
| ziprasidone_substrate_of_cyp2c19 | 1 |
| ziprasidone_substrate_of_cyp2c9 | 1 |
| ziprasidone_substrate_of_cyp2d6 | 1 |
| ziprasidone_substrate_of_cyp3a4 | 1 |
| zolpidem | 1 |
| zolpidem_is_not_substrate_of_cyp3a4 | 1 |
| zolpidem_is_not_substrate_of_cyp3a5 | 1 |
| zolpidem_maximum_concentration_continuous_value | 1 |
| zolpidem_substrate_of_cyp3a4 | 1 |
| zolpidem_substrate_of_cyp3a5 | 1 |
| {(1s)-1-Benzyl-4-[3-Carbamoyl-1-(1-Carbamoyl-2-Phenyl-Ethylcarbamoyl)-(S)-Propylcarbamoyl]-2-Oxo-5-Phenyl-Pentyl}-Carbamic Acid Tert-Butyl Ester | 1 |
| {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate | 1 |
| {(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide | 1 |
| {(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE | 1 |
| {1-[(3-Hydroxy-Methyl-5-Phosphonooxy-Methyl-Pyridin-4-Ylmethyl)-Amino]-Ethyl}-Phosphonic Acid | 1 |
| {1-[2-(1-FORMYL-PROPYL)-3-METHANESULFONYLAMINO-PYRROLIDINE-1-CARBONYL]-2-METHYL-PROPYL}-CARBAMIC ACID TERT-BUTYL ESTER | 1 |
| {3-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-2-Methyl-Propyl}-Phosphonic Acid | 1 |
| {3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID | 1 |
| {3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID | 1 |
| {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid | 1 |
| {4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone | 1 |
| {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid | 1 |
| {4-[(CARBOXYMETHOXY)CARBONYL]-3,3-DIOXIDO-1-OXONAPHTHO[1,2-D]ISOTHIAZOL-2(1H)-YL}ACETIC ACID | 1 |
| {4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID | 1 |
| {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid | 1 |
| {4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID | 1 |
| {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid | 1 |
| {4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol | 1 |
| {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid | 1 |
| {5-(5-AMINO-1H-PYRROLO[3,2-B]PYRIDIN-2-YL)-6-HYDROXY-3'-NITRO-BIPHENYL-3-YL]-ACETIC ACID | 1 |
| {[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid | 1 |
| {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide | 1 |
| {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) | 1 |
| {[4-AMINO-2-(3-CHLOROANILINO)-1,3-THIAZOL-5-YL](4-FLUOROPHENYL)METHANONE | 1 |
| {[5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOL-2-YL]THIO}ACETIC ACID | 1 |
| {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid | 1 |
